600422.SS
600422.SS
CNE0000015P8
KPC PHARMACEUTICALS INC
Loading chart...

Company Profile

KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People's Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, comether tablets, specialty herbal products, classic prescription for bones and joint, antibiotics, immunosuppressive, oral products, injections, and other products, as well as engages in the wholesale and retail of medicines and equipment. The company offers products in the field of cardiovascular and cerebrovascular, orthopedics series, antimalarial, gynecology, digestive system, and others treatments. It offers its products under Luotai, Tianxuanqing, Artemedine, Artem, and Arco brands. The company was formerly known as Kunming Pharmaceutical Corporation and changed its name to KPC Pharmaceuticals, Inc. in April 2015. KPC Pharmaceuticals,Inc. was founded in 1951 and is based in Kunming, the People's Republic of China.

Related stocks

002907.SZ
002907.SZ • China
PHARSCIN PHARMA
15.44 CNY
964.79M USD 1Y -4.9%
002038.SZ
002038.SZ • China
SL PHARM
5.76 CNY
885.46M USD 1Y -20.3%
300705.SZ
300705.SZ • China
JIUDIAN
11.23 CNY
840.68M USD 1Y -34%
600488.SS
600488.SS • China
TIANJIN TIANYAO PHARMACEUTICAL
6.47 CNY
1.06B USD 1Y +59%
000566.SZ
000566.SZ • China
HAINAN HAIYAO
4.71 CNY
914.35M USD 1Y -13.7%
000915.SZ
000915.SZ • China
WIT DYNE
24.22 CNY
849.25M USD 1Y -23.8%
603538.SS
603538.SS • China
NINGBO MENOVO PHARMACEUTICAL CO
28.45 CNY
1.45B USD 1Y +80%
000597.SZ
000597.SZ • China
NEP.
4.91 CNY
1.05B USD 1Y -10.2%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
40.0% p.a.
Max Drawdown (5Y)
-69.0%
Sharpe Ratio (5Y)
-0.10
Beta Factor
-0.17
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (40.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -69.0% in the extended horizon.
ende